N-(4-氯-2-三氟乙酰基-6-甲氧基苯基)-2,2-二甲基丙酰胺 | 1076199-86-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N-(4-氯-2-三氟乙酰基-6-甲氧基苯基)-2,2-二甲基丙酰胺
• 中文别名: N-（4-氯-2-三氟乙酰基-6-甲氧基苯基）-2,2-二甲基丙酰胺
• 英文名称: N-[4-Chloro-2-methoxy-6-(2,2,2-trifluoro-acetyl)-phenyl]-2,2-dimethyl-propionamide
• 英文别名: N-(4-Chloro-2-trifluoroacetyl-6-methoxyphenyl)-2,2-dimethylpropanamide；N-[4-chloro-2-methoxy-6-(2,2,2-trifluoroacetyl)phenyl]-2,2-dimethylpropanamide
• CAS: 1076199-86-4
• 化学式: C₁₄H₁₅ClF₃NO₃
• 分子量: 337.726
• InChiKey: YYVHOCLUSDEOTG-UHFFFAOYSA-N

物化性质

• 沸点：
  406.1±45.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二氯甲烷、二甲基亚砜、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(4-氯-2-三氟乙酰基-6-甲氧基苯基)-2,2-二甲基丙酰胺 在 咪唑 、 盐酸 、 三溴化硼 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 6-氯-4-(2-环丙基乙炔基)-8-[[(叔丁基)二甲基硅烷基]氧基]-1,4-二氢-4-(三氟甲基)-2H-3,1-苯并恶嗪-2-酮
  参考文献：
  名称：

  Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz

  摘要：

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00012-9
• 作为产物：
  描述：

  4-氯-2-甲氧基苯胺 在 仲丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 N-(4-氯-2-三氟乙酰基-6-甲氧基苯基)-2,2-二甲基丙酰胺
  参考文献：
  名称：

  Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz

  摘要：

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00012-9

文献信息

• Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors
  作者：Mona Patel、Soo S. Ko、Robert J. McHugh、Jay A. Markwalder、Anurag S. Srivastava、Beverly C. Cordova、Ronald M. Klabe、Susan Erickson-Viitanen、George L. Trainor、Steven.P. Seitz

  DOI：10.1016/s0960-894x(99)00486-2

  日期：1999.10

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.
• Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor Efavirenz
  作者：Jay A. Markwalder、David D. Christ、Abdul Mutlib、Beverly C. Cordova、Ronald M. Klabe、Steven P. Seitz

  DOI：10.1016/s0960-894x(01)00012-9

  日期：2001.3

  Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in vivo. We have synthesized metabolites of efavirenz to confirm their structure and to evaluate their activity as antivirals. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.